Arizona State Retirement System Has $461,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Arizona State Retirement System increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,733 shares of the biopharmaceutical company’s stock after buying an additional 654 shares during the period. Arizona State Retirement System’s holdings in Catalyst Pharmaceuticals were worth $461,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in CPRX. Vanguard Group Inc. lifted its position in Catalyst Pharmaceuticals by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares in the last quarter. Janus Henderson Group PLC lifted its position in Catalyst Pharmaceuticals by 139.5% in the 1st quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after acquiring an additional 1,587,794 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Catalyst Pharmaceuticals by 1.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company’s stock valued at $43,738,000 after acquiring an additional 41,923 shares in the last quarter. Opaleye Management Inc. lifted its position in Catalyst Pharmaceuticals by 4.3% in the 4th quarter. Opaleye Management Inc. now owns 1,257,200 shares of the biopharmaceutical company’s stock valued at $21,436,000 after acquiring an additional 52,200 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Catalyst Pharmaceuticals by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock valued at $19,439,000 after acquiring an additional 22,860 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on CPRX shares. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. Truist Financial lifted their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright lifted their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Citigroup lifted their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $29.50.

Catalyst Pharmaceuticals Trading Up 1.1 %

NASDAQ:CPRX opened at $20.44 on Tuesday. The stock has a market capitalization of $2.43 billion, a PE ratio of 37.85, a price-to-earnings-growth ratio of 3.10 and a beta of 0.75. The firm’s 50 day moving average is $18.42 and its 200 day moving average is $16.67. Catalyst Pharmaceuticals, Inc. has a 12 month low of $11.55 and a 12 month high of $20.87.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. The company had revenue of $122.71 million for the quarter, compared to analysts’ expectations of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. Research analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 201,058 shares of company stock valued at $4,018,188. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.